Evidence map›Paper›PMID 21360099›Full record

ReviewPsychopharmacology2011

Neuroimaging and drug taking in primates.

Kevin S Murnane, Leonard L Howell

Abstract readReview
In one paragraph

Review in Psychopharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.2field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Review
  3. Noninvasive Vagal Nerve Stimulation for Opioid Use Disorder.Annals of depression and anxiety · 2023
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. The serotonin 5-HTJournal of psychopharmacology (Oxford, England) · 2017
    Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Kevin S MurnaneYerkes National Primate Research Center, Emory University, 954 Gatewood Road NE, Atlanta, GA 30329, USA.
Leonard L Howell
Emory University · US

Funding

YNPRC NHP CLINICAL MEDICINE RESIDENCY PROGRAM - SUPPLEMENTP51RR000165 · NCRR · EMORY UNIVERSITY · PI ALTMAN, JOHN DAVID · 1985 to 2011
$114.0M
COCAINE USE AND MONOAMINE FUNCTION IN NONHUMAN PRIMATESR01DA012514 · NIDA · EMORY UNIVERSITY · PI HOWELL, LEONARD L · 2000 to 2014
$5.5M
PET Imaging and Cocaine Neuropharmacology in MonkeysR37DA010344 · NIDA · EMORY UNIVERSITY · PI HOWELL, LEONARD L · 2007 to 2015
$4.9M
PET IMAGING AND COCAINE NEUROPHARMACOLOGY IN MONKEYSR01DA010344 · NIDA · EMORY UNIVERSITY · PI HOWELL, LEONARD L · 1997 to 2006
$2.7M
Transitional States in Drug AddictionR01DA016589 · NIDA · EMORY UNIVERSITY · PI HOWELL, LEONARD L · 2003 to 2007
$2.2M
The mt-DNA mutator mouseZ01DA000517 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI HOFFER, BARRY J · 2007 to 2008
$1.1M
Neuropharmacology of Cocaine in Nonhuman PrimatesK02DA000517 · NIDA · EMORY UNIVERSITY · PI HOWELL, LEONARD L · 2001 to 2010
$1.1M
Intramural NIH HHS Z01 DA000517NCRR NIH HHS P51 RR000165NCRR NIH HHS RR00165NIDA NIH HHS DA10344NIDA NIH HHS DA12514NIDA NIH HHS DA16589NIDA NIH HHS K02 DA000517NIDA NIH HHS R01 DA010344NIDA NIH HHS R01 DA012514NIDA NIH HHS R01 DA016589NIDA NIH HHS R37 DA010344
6 · The paper itself

Abstract

rationaleNeuroimaging techniques have led to significant advances in our understanding of the neurobiology of drug taking and the treatment of drug addiction in humans. Neuroimaging approaches provide a powerful translational approach that can link findings from humans and laboratory animals.

objectiveThis review describes the utility of neuroimaging toward understanding the neurobiological basis of drug taking and documents the close concordance that can be achieved among neuroimaging, neurochemical, and behavioral endpoints.

resultsThe study of drug interactions with dopamine and serotonin transporters in vivo has identified pharmacological mechanisms of action associated with the abuse liability of stimulants. Neuroimaging has identified the extended limbic system, including the prefrontal cortex and anterior cingulate, as important neuronal circuitry that underlies drug taking. The ability to conduct within-subject longitudinal assessments of brain chemistry and neuronal function has enhanced our efforts to document long-term changes in dopamine D2 receptors, monoamine transporters, and prefrontal metabolism due to chronic drug exposure. Dysregulation of dopamine function and brain metabolic changes in areas involved in reward circuitry have been linked to drug taking behavior, cognitive impairment, and treatment response.

conclusionsExperimental designs employing neuroimaging should consider well-documented determinants of drug taking, including pharmacokinetic considerations, subject history, and environmental variables. Methodological issues to consider include limited molecular probes, lack of neurochemical specificity in brain activation studies, and the potential influence of anesthetics in animal studies. Nevertheless, these integrative approaches should have important implications for understanding drug taking behavior and the treatment of drug addiction.

Indexed as

AnimalsBrain ChemistryDiagnostic ImagingDopamineDopamine Plasma Membrane Transport ProteinsHumansPharmaceutical PreparationsPrimatesSerotoninSerotonin Plasma Membrane Transport ProteinsSubstance-Related DisordersDopamineDopamine Plasma Membrane Transport ProteinsPharmaceutical PreparationsSerotoninSerotonin Plasma Membrane Transport Proteins

Identifiers

PMID21360099
PMCPMC3232674
OpenAlexW2046615190

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.